2595202-07-4
2595202-07-4
Chemical Structure
BPI-361175
- CAS. Nr.: 2595202-07-4
- Formula:C30H37BrN7O3P
- Molecular Weight:654.54
InChIKey: NQSSRYPGALNKIZ-UHFFFAOYSA-N
SMILES: CCN1C=C(C=N1)C2=CC(NC3=NC(NC4=CC=C(C(C)=C4P(C)(C)=O)C)=C(C=N3)Br)=C(C=C2N5CCOCC5)OC
Biological Activity: BPI-361175 is an orally active and blood-brain barrier-penetrant EGFR inhibitor. BPI-361175 inhibits EGFR tyrosine kinase activity and exhibits higher selectivity for mutant EGFR over wild-type EGFR. BPI-361175 can be used for research on non-small cell lung cancer[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BPI-361175 | BPI-361175 is an orally active and blood-brain barrier-penetrant EGFR inhibitor. BPI-361175 inhibits EGFR tyrosine kinase activity and exhibits higher selectivity for mutant EGFR over wild-type EGFR. BPI-361175 can be used for research on non-small cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kadam VM, et al. Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC). Bioorganic chemistry. 2026 Oct 05;181:110353.
- [2]. Liu L, e al. Abstract 5462: BPI-361175, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC). Cancer Res. 2022;82(12_Supplement):5462.
